Hemab Doses First Participant in HMB-003 Phase 1
CAMBRIDGE, Mass. and COPENHAGEN, Denmark — September 17, 2026 Hemab Therapeutics announced that the first healthy volunteer has been...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
CAMBRIDGE, Mass. and COPENHAGEN, Denmark — September 17, 2026 Hemab Therapeutics announced that the first healthy volunteer has been...
CAMBRIDGE, Mass. and COPENHAGEN, Denmark, July 14, 2026 Hemab Therapeutics presented new clinical and preclinical data at the International...
BOSTON, April 24, 2026 Haemonetics Corporation has announced compelling new clinical data demonstrating the safety, efficacy, and superior performance...
